User profiles for Adeel A. Butt

Adeel A. Butt

Professor of Medicine and Professor of Population Health Sciences, Weill Cornell Medical …
Verified email at med.cornell.edu
Cited by 22856

Veterans aging cohort study (VACS): overview and description

…, T Madenwald, J Goulet, M Simberkoff, AA Butt… - Medical care, 2006 - journals.lww.com
Background: The Veterans Aging Cohort Study (VACS) is a study of human immunodeficiency
virus (HIV) infected and uninfected patients seen in infectious disease and general …

Infections related to the ingestion of seafood Part I: viral and bacterial infections

AA Butt, KE Aldridge, CV Sanders - The Lancet infectious diseases, 2004 - thelancet.com
Foodborne diseases cause an estimated 76 million illnesses in the USA each year. Seafood
is implicated in 10–19% of these illnesses. A causative agent can be traced in about 44% of …

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B. 1.1. 7 and B. 1.351 Variants

…, H Chemaitelly, AA Butt - New England Journal of …, 2021 - Mass Medical Soc
Efficacy of the BNT162b2 mRNA Vaccine in Qatar As of March 31, 2021, more than 265,000
people in Qatar had received both doses of the BNT162b2 vaccine. Viral sequencing …

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar

…, MG Al Kuwari, HE Al Romaihi, AA Butt… - … England Journal of …, 2021 - Mass Medical Soc
Background Waning of vaccine protection against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The …

Boceprevir and telaprevir in the management of hepatitis C virus–infected patients

AA Butt, F Kanwal - Clinical infectious diseases, 2012 - academic.oup.com
Recent approval of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV)
offers a major advance in the management of HCV infection. These DAAs, boceprevir and …

Effects of previous infection and vaccination on symptomatic omicron infections

…, GK Nasrallah, MG Al-Kuwari, AA Butt… - … England Journal of …, 2022 - Mass Medical Soc
Background The protection conferred by natural immunity, vaccination, and both against
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the …

Protection against the Omicron variant from previous SARS-CoV-2 infection

…, GK Nasrallah, MG Al-Kuwari, AA Butt… - … England Journal of …, 2022 - Mass Medical Soc
Protection against Omicron by Previous SARS-CoV-2 Infection Using a national Covid-19
database in Qatar, investigators found that previous SARS-CoV-2 infection provided protection …

Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar

…, GK Nasrallah, MG Al-Kuwari, AA Butt… - … England Journal of …, 2022 - Mass Medical Soc
Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19)
and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory …

HIV infection and the risk of acute myocardial infarction

…, E Lowy, KL Kraemer, AA Butt… - JAMA internal …, 2013 - jamanetwork.com
Importance Whether people infected with human immunodeficiency virus (HIV) are at an
increased risk of acute myocardial infarction (AMI) compared with uninfected people is not clear…

mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar

…, HE Al Romaihi, MH Al-Thani, A Al Khal, AA Butt… - Nature medicine, 2021 - nature.com
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna)
vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-…